Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2010

01-12-2010 | Short Research Report

Cost reduction associated with restriction policy on dispensing intravenous esomeprazole in lebanon

Authors: Soumana C. Nasser, Jeanette G. Nassif, Fouad Mahfouz

Published in: International Journal of Clinical Pharmacy | Issue 6/2010

Login to get access

Abstract

Objectives To assess the impact of the pharmacist on cost through simple implementation of restriction policy on IV drug usage during pharmacy dispensing procedure. Setting In-patient floors of a Hospital. Methods All medication orders for IV esomeprazole, received at the pharmacy during a 24-month period, were reviewed for appropriate IV route of administration. Two separate time intervals, pre- and post- implementation of restriction dispensing policy, were used to determine cost impact of pharmacy intervention. Main Outcome Measure The cost difference between pre- and post-restriction periods. Results During the pre-restriction period, the majority of esomeprazole IV vials were dispensed to patients able to tolerate oral medications and who were admitted to non-intensive care units. The average monthly consumption of IV esomeprazole was 1,439 vials in the pre-restriction period as compared to 346 vials in the post-restriction period. Therefore, the associated cost was reduced by an average of $21,233 per month. Conclusion Even though the clinical role of pharmacy practice in Middle Eastern countries is limited, this study highlighted the impact of the pharmacist on cost through the implementation of restriction policy during dispensing procedure, leading to a cost reduction by four folds.
Literature
1.
go back to reference George CJ, Korc B, Ross JS. Appropriate Proton Pump Inhibitor Use Among Older Adults: a Retrospective Chart Review. Am Geriatr Pharmacother. 2008;6:249–54.CrossRef George CJ, Korc B, Ross JS. Appropriate Proton Pump Inhibitor Use Among Older Adults: a Retrospective Chart Review. Am Geriatr Pharmacother. 2008;6:249–54.CrossRef
2.
go back to reference Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103(5):327–35.CrossRefPubMed Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103(5):327–35.CrossRefPubMed
3.
go back to reference Schneider H, Van Rensburg C, Schmidt S, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitos. Digestion. 2004;70:250–6.CrossRefPubMed Schneider H, Van Rensburg C, Schmidt S, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitos. Digestion. 2004;70:250–6.CrossRefPubMed
4.
go back to reference Metz DC, Miner PB, Heuman DM, et al. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastroesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:813–21.CrossRefPubMed Metz DC, Miner PB, Heuman DM, et al. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastroesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:813–21.CrossRefPubMed
5.
go back to reference Rosh’s KM, Bondarov P, Lundgren M, et al. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides a similar level of acid control as oral administration in healthy subjects [abstract no. S1611]. Gastroenterology. 2003;124(4 Suppl. 1):A231. Rosh’s KM, Bondarov P, Lundgren M, et al. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides a similar level of acid control as oral administration in healthy subjects [abstract no. S1611]. Gastroenterology. 2003;124(4 Suppl. 1):A231.
7.
go back to reference Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci. 2008;54(9):1947–52.CrossRefPubMed Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci. 2008;54(9):1947–52.CrossRefPubMed
9.
go back to reference Altavela JL, Jones MK, Ritter M. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. J Manag Care Pharm. 2008;14(9):831–43.PubMed Altavela JL, Jones MK, Ritter M. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. J Manag Care Pharm. 2008;14(9):831–43.PubMed
10.
go back to reference Ramser KL, Sprabery LR, Hamann GL, George CM, Will A. Results of an intervention in an academic internal medicine clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change. J Manag Care Pharm. 2009;15(4):344–50.PubMed Ramser KL, Sprabery LR, Hamann GL, George CM, Will A. Results of an intervention in an academic internal medicine clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change. J Manag Care Pharm. 2009;15(4):344–50.PubMed
Metadata
Title
Cost reduction associated with restriction policy on dispensing intravenous esomeprazole in lebanon
Authors
Soumana C. Nasser
Jeanette G. Nassif
Fouad Mahfouz
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9451-4

Other articles of this Issue 6/2010

International Journal of Clinical Pharmacy 6/2010 Go to the issue